These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24682224)

  • 1. Association of variants in DRD2 and GRM3 with motor and cognitive function in first-episode psychosis.
    Lencer R; Bishop JR; Harris MS; Reilly JL; Patel S; Kittles R; Prasad KM; Nimgaonkar VL; Keshavan MS; Sweeney JA
    Eur Arch Psychiatry Clin Neurosci; 2014 Jun; 264(4):345-55. PubMed ID: 24682224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia.
    Bishop JR; Reilly JL; Harris MS; Patel SR; Kittles R; Badner JA; Prasad KM; Nimgaonkar VL; Keshavan MS; Sweeney JA
    Psychopharmacology (Berl); 2015 Jan; 232(1):145-54. PubMed ID: 25096017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis.
    Miura I; Zhang JP; Hagi K; Lencz T; Kane JM; Yabe H; Malhotra AK; Correll CU
    Psychoneuroendocrinology; 2016 Oct; 72():1-10. PubMed ID: 27333159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis.
    Zhang JP; Robinson DG; Gallego JA; John M; Yu J; Addington J; Tohen M; Kane JM; Malhotra AK; Lencz T
    Schizophr Bull; 2015 Nov; 41(6):1248-55. PubMed ID: 26320194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variants of D2 but not D3 or D4 dopamine receptor gene are associated with rapid onset and poor prognosis of methamphetamine psychosis.
    Ujike H; Katsu T; Okahisa Y; Takaki M; Kodama M; Inada T; Uchimura N; Yamada M; Iwata N; Sora I; Iyo M; Ozaki N; Kuroda S
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Jun; 33(4):625-9. PubMed ID: 19275926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensorimotor transformation deficits for smooth pursuit in first-episode affective psychoses and schizophrenia.
    Lencer R; Reilly JL; Harris MS; Sprenger A; Keshavan MS; Sweeney JA
    Biol Psychiatry; 2010 Feb; 67(3):217-23. PubMed ID: 19782964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabotropic glutamate receptor 3 is associated with heroin dependence but not depression or schizophrenia in a Chinese population.
    Jia W; Zhang R; Wu B; Dai ZX; Zhu YS; Li PP; Zhu F
    PLoS One; 2014; 9(1):e87247. PubMed ID: 24498053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of methylation and -141C Ins/Del polymorphisms of the dopamine receptor D2 gene in patients with schizophrenia.
    Funahashi Y; Yoshino Y; Yamazaki K; Ozaki Y; Mori Y; Mori T; Ochi S; Iga JI; Ueno SI
    Psychiatry Res; 2019 Aug; 278():135-140. PubMed ID: 31176829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients.
    Suzuki A; Kondo T; Mihara K; Yasui-Furukori N; Ishida M; Furukori H; Kaneko S; Inoue Y; Otani K
    Pharmacogenetics; 2001 Aug; 11(6):545-50. PubMed ID: 11505224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between the DRD2-141C Insertion/Deletion polymorphism and schizophrenia.
    Cordeiro Q; Siqueira-Roberto J; Zung S; Vallada H
    Arq Neuropsiquiatr; 2009 Jun; 67(2A):191-4. PubMed ID: 19547807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.
    Lencz T; Robinson DG; Xu K; Ekholm J; Sevy S; Gunduz-Bruce H; Woerner MG; Kane JM; Goldman D; Malhotra AK
    Am J Psychiatry; 2006 Mar; 163(3):529-31. PubMed ID: 16513877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of second-generation antipsychotic medication on smooth pursuit performance in antipsychotic-naive schizophrenia.
    Lencer R; Sprenger A; Harris MS; Reilly JL; Keshavan MS; Sweeney JA
    Arch Gen Psychiatry; 2008 Oct; 65(10):1146-54. PubMed ID: 18838631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between Dopamine Receptor D2 (DRD2) Variations rs6277 and rs1800497 and Cognitive Performance According to Risk Type for Psychosis: A Nested Case Control Study in a Finnish Population Sample.
    Ramsay H; Barnett JH; Miettunen J; Mukkala S; Mäki P; Liuhanen J; Murray GK; Jarvelin MR; Ollila H; Paunio T; Veijola J
    PLoS One; 2015; 10(6):e0127602. PubMed ID: 26114663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vulnerable combinations of functional dopaminergic polymorphisms to late-onset treatment resistant schizophrenia.
    Oishi K; Kanahara N; Takase M; Oda Y; Nakata Y; Niitsu T; Ishikawa M; Sato Y; Iyo M
    PLoS One; 2018; 13(11):e0207133. PubMed ID: 30408108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.
    Alenius M; Wadelius M; Dahl ML; Hartvig P; Lindström L; Hammarlund-Udenaes M
    J Psychiatr Res; 2008 Sep; 42(11):884-93. PubMed ID: 18086475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association analysis of group II metabotropic glutamate receptor genes (GRM2 and GRM3) with mood disorders and fluvoxamine response in a Japanese population.
    Tsunoka T; Kishi T; Ikeda M; Kitajima T; Yamanouchi Y; Kinoshita Y; Kawashima K; Okochi T; Okumura T; Inada T; Ozaki N; Iwata N
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Aug; 33(5):875-9. PubMed ID: 19386277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C957T polymorphism of the human dopamine D2 receptor gene predicts extrastriatal dopamine receptor availability in vivo.
    Hirvonen MM; Lumme V; Hirvonen J; Pesonen U; Någren K; Vahlberg T; Scheinin H; Hietala J
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Jun; 33(4):630-6. PubMed ID: 19285111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide association studies of smooth pursuit and antisaccade eye movements in psychotic disorders: findings from the B-SNIP study.
    Lencer R; Mills LJ; Alliey-Rodriguez N; Shafee R; Lee AM; Reilly JL; Sprenger A; McDowell JE; McCarroll SA; Keshavan MS; Pearlson GD; Tamminga CA; Clementz BA; Gershon ES; Sweeney JA; Bishop JR
    Transl Psychiatry; 2017 Oct; 7(10):e1249. PubMed ID: 29064472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DRD3, but not COMT or DRD2, genotype affects executive functions in healthy and first-episode psychosis adolescents.
    Bombin I; Arango C; Mayoral M; Castro-Fornieles J; Gonzalez-Pinto A; Gonzalez-Gomez C; Moreno D; Parellada M; Baeza I; Graell M; Otero S; Saiz PA; Patiño-Garcia A
    Am J Med Genet B Neuropsychiatr Genet; 2008 Sep; 147B(6):873-9. PubMed ID: 18351593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis.
    Colizzi M; Iyegbe C; Powell J; Ursini G; Porcelli A; Bonvino A; Taurisano P; Romano R; Masellis R; Blasi G; Morgan C; Aitchison K; Mondelli V; Luzi S; Kolliakou A; David A; Murray RM; Bertolino A; Di Forti M
    Schizophr Bull; 2015 Sep; 41(5):1171-82. PubMed ID: 25829376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.